關於我們 - 新藥研發公司 | 台睿生技 New Drug Development

Meet TaiRx

TaiRx, Inc. was established in 2011 with the goal of developing next-generation therapeutics for cancer treatment. Since 2013, TaiRx has progressively expanded its operations while broadening its product pipeline. In addition to novel oncology therapeutics, TaiRx has extended its research and development efforts to treatments for other serious diseases. Several drug candidates have advanced into human clinical trials, and one product has received marketing approval, demonstrating TaiRx’s ability to advance drug development programs from research through clinical development and commercialization.

Building on its foundation in Taiwan, TaiRx has assembled a network of highly experienced international experts and advisors across multiple disciplines. By leveraging the technical expertise of its R&D team, TaiRx continues to enhance the value of its pipeline through the advancement of preclinical and clinical development programs. TaiRx is committed to scientific excellence and high-quality drug development while strengthening international collaborations and actively expanding its global partnering and licensing activities. Through these efforts, TaiRx aims to establish itself as a globally competitive, innovation-driven pharmaceutical company dedicated to the development and commercialization of innovative therapeutics.

Vision

TaiRx is an R&D-driven pharmaceutical company that leverages global expertise to develop innovative therapeutics for Asian and global markets. Our team brings extensive knowledge and decades of experience in global drug development, enabling us to efficiently advance promising drug candidates from early-stage research into clinical development. We are committed to addressing unmet medical needs and improving the health and quality of life of patients worldwide.

We dedicate ourselves to:

公司發展策略

Advancing innovative drug candidates through preclinical and clinical development while building strong global intellectual property portfolio and maximize product value.

Establishing strategic commercial partnerships across the Asia-Pacific region and building strong sales, marketing, and distribution networks to maximize the market potential of our products.

Collaborating with global pharmaceutical and biotechnology companies to accelerate late-stage development, expand global licensing opportunities, and bring innovative therapies to patients worldwide.

Attracting and developing highly qualified professionals in drug development, and building an integrated, multidisciplinary team with capabilities that meet global standards.

Continuously evaluating and in-licensing promising drug candidates with strong scientific and commercial potential to strengthen our pipeline and support sustainable long-term growth.

History

2011

TaiRx was officially established on August 22, with a primary focus on developing next-generation cancer therapeutics.

2015

CVM-1118, TaiRx’s lead oral small-molecule anticancer drug candidate, received U.S. FDA IND clearance and entered a Phase I clinical trial (CVM-001).
Received the Bronze Award at the Taipei Biotech Awards.
Received the Excellence Award at the Taiwan Biomedical and New Agriculture Innovation Selection Competition.
CVM-1118 received the Enterprise Innovation Award at the National Innovation Award.

2016

CVM-1118 entered a Phase I clinical trial in Taiwan (CVM-002).

2017

Rexis^®, a novel drug candidate for sepsis, received TFDA approval to initiate a multicenter Phase III clinical trial in Taiwan (MOFI-001).
TaiRx was officially registered on the Emerging Stock Market of the Taipei Exchange (TPEx) under stock code 6580.
TaiRx entered into a licensing agreement with Northwestern University in the United States, obtaining global rights to develop Nodal-targeted approaches for cancer diagnosis and treatment.